Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 6 | 2026 | 166 | 2.850 |
Why?
|
| Colonic Neoplasms | 4 | 2021 | 122 | 1.670 |
Why?
|
| Cell Proliferation | 9 | 2026 | 825 | 1.190 |
Why?
|
| Apoptosis | 6 | 2026 | 780 | 1.110 |
Why?
|
| Signal Transduction | 7 | 2026 | 1470 | 1.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2026 | 472 | 0.990 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2026 | 32 | 0.960 |
Why?
|
| Adenocarcinoma | 4 | 2021 | 300 | 0.920 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2026 | 157 | 0.890 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2025 | 13 | 0.890 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2025 | 20 | 0.890 |
Why?
|
| Spheroids, Cellular | 1 | 2024 | 53 | 0.850 |
Why?
|
| STAT3 Transcription Factor | 1 | 2024 | 97 | 0.830 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 104 | 0.830 |
Why?
|
| Adenoma | 2 | 2021 | 61 | 0.810 |
Why?
|
| Neoplasms | 4 | 2025 | 879 | 0.800 |
Why?
|
| Cell Survival | 1 | 2024 | 419 | 0.770 |
Why?
|
| Antineoplastic Agents | 7 | 2021 | 686 | 0.750 |
Why?
|
| Pyrroles | 3 | 2015 | 36 | 0.650 |
Why?
|
| Alendronate | 1 | 2019 | 6 | 0.620 |
Why?
|
| Neoplastic Stem Cells | 3 | 2024 | 141 | 0.620 |
Why?
|
| Anticarcinogenic Agents | 1 | 2019 | 16 | 0.620 |
Why?
|
| Animals | 22 | 2025 | 10715 | 0.620 |
Why?
|
| Metformin | 1 | 2019 | 36 | 0.610 |
Why?
|
| Neoplasms, Experimental | 1 | 2019 | 58 | 0.610 |
Why?
|
| Colorectal Neoplasms | 4 | 2022 | 142 | 0.560 |
Why?
|
| Pancreatic Neoplasms | 7 | 2019 | 548 | 0.540 |
Why?
|
| Uroplakin II | 2 | 2014 | 5 | 0.530 |
Why?
|
| Antigens, Polyomavirus Transforming | 2 | 2014 | 5 | 0.530 |
Why?
|
| Carcinoma in Situ | 4 | 2019 | 46 | 0.500 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2019 | 146 | 0.500 |
Why?
|
| Azoxymethane | 3 | 2021 | 20 | 0.490 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2015 | 82 | 0.480 |
Why?
|
| Muscles | 1 | 2015 | 73 | 0.460 |
Why?
|
| Rats | 4 | 2024 | 1592 | 0.450 |
Why?
|
| Mice | 14 | 2024 | 4815 | 0.430 |
Why?
|
| Phytochemicals | 2 | 2016 | 9 | 0.430 |
Why?
|
| Lipoxygenase | 1 | 2014 | 3 | 0.430 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2014 | 24 | 0.420 |
Why?
|
| Cell Line, Tumor | 5 | 2026 | 1351 | 0.420 |
Why?
|
| Biomarkers, Tumor | 3 | 2020 | 415 | 0.410 |
Why?
|
| Phytotherapy | 1 | 2013 | 22 | 0.400 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2015 | 128 | 0.390 |
Why?
|
| Mice, Transgenic | 7 | 2021 | 514 | 0.390 |
Why?
|
| Cell Movement | 3 | 2026 | 376 | 0.390 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 56 | 0.390 |
Why?
|
| Pyrimidines | 1 | 2013 | 128 | 0.370 |
Why?
|
| Inflammation | 2 | 2015 | 668 | 0.370 |
Why?
|
| Naproxen | 3 | 2021 | 15 | 0.360 |
Why?
|
| Humans | 19 | 2026 | 28998 | 0.350 |
Why?
|
| Neoplasm Invasiveness | 4 | 2019 | 190 | 0.350 |
Why?
|
| Rats, Inbred F344 | 2 | 2021 | 174 | 0.320 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2021 | 62 | 0.310 |
Why?
|
| Epithelial Cells | 1 | 2011 | 266 | 0.310 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 3 | 2020 | 19 | 0.300 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2014 | 329 | 0.240 |
Why?
|
| Carcinogens | 3 | 2021 | 39 | 0.240 |
Why?
|
| Deoxycytidine | 1 | 2026 | 67 | 0.230 |
Why?
|
| Down-Regulation | 1 | 2026 | 202 | 0.230 |
Why?
|
| Nucleosomes | 1 | 2025 | 18 | 0.220 |
Why?
|
| Sirolimus | 2 | 2015 | 76 | 0.220 |
Why?
|
| Male | 10 | 2021 | 13983 | 0.220 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 360 | 0.220 |
Why?
|
| Organoids | 1 | 2024 | 23 | 0.220 |
Why?
|
| Chromatin | 1 | 2025 | 76 | 0.210 |
Why?
|
| Urinary Bladder | 2 | 2015 | 119 | 0.200 |
Why?
|
| Quinazolines | 2 | 2015 | 32 | 0.200 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2021 | 120 | 0.200 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 137 | 0.180 |
Why?
|
| Administration, Oral | 2 | 2019 | 191 | 0.180 |
Why?
|
| Drug Synergism | 2 | 2019 | 106 | 0.180 |
Why?
|
| Phyllanthus emblica | 1 | 2021 | 2 | 0.180 |
Why?
|
| Ribes | 1 | 2021 | 2 | 0.180 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 1511 | 0.180 |
Why?
|
| Chemoprevention | 5 | 2019 | 32 | 0.180 |
Why?
|
| Omeprazole | 1 | 2021 | 9 | 0.180 |
Why?
|
| Aspirin | 2 | 2019 | 125 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 612 | 0.170 |
Why?
|
| Proton Pump Inhibitors | 1 | 2021 | 27 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 79 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 843 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2020 | 82 | 0.160 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 2019 | 8 | 0.150 |
Why?
|
| Mutation | 2 | 2021 | 871 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 210 | 0.150 |
Why?
|
| Lipoxygenase Inhibitors | 2 | 2015 | 16 | 0.150 |
Why?
|
| Receptors, Enterotoxin | 1 | 2018 | 5 | 0.140 |
Why?
|
| Paracrine Communication | 1 | 2018 | 17 | 0.140 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2018 | 19 | 0.140 |
Why?
|
| Cyclic GMP | 1 | 2018 | 29 | 0.140 |
Why?
|
| Hormones | 1 | 2018 | 44 | 0.140 |
Why?
|
| Blotting, Western | 3 | 2014 | 515 | 0.140 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 465 | 0.140 |
Why?
|
| Female | 9 | 2021 | 15690 | 0.130 |
Why?
|
| Immunoenzyme Techniques | 2 | 2014 | 66 | 0.130 |
Why?
|
| Cyclooxygenase 2 | 4 | 2020 | 68 | 0.130 |
Why?
|
| Chromans | 1 | 2017 | 59 | 0.130 |
Why?
|
| Thiones | 1 | 2017 | 55 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 133 | 0.130 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2016 | 16 | 0.120 |
Why?
|
| Polyamines | 1 | 2015 | 13 | 0.120 |
Why?
|
| Mucin-1 | 1 | 2016 | 36 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 347 | 0.120 |
Why?
|
| Pancreatitis | 1 | 2015 | 36 | 0.110 |
Why?
|
| RNA, Messenger | 2 | 2014 | 668 | 0.110 |
Why?
|
| Tobacco | 1 | 2015 | 87 | 0.110 |
Why?
|
| Eflornithine | 1 | 2014 | 3 | 0.110 |
Why?
|
| Ornithine Decarboxylase | 1 | 2014 | 9 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 148 | 0.110 |
Why?
|
| Urothelium | 1 | 2014 | 35 | 0.110 |
Why?
|
| CD13 Antigens | 1 | 2014 | 26 | 0.110 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 37 | 0.100 |
Why?
|
| Technetium | 1 | 2014 | 43 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2014 | 97 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 29 | 0.100 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2013 | 37 | 0.100 |
Why?
|
| Peptides | 2 | 2014 | 297 | 0.100 |
Why?
|
| Molecular Structure | 1 | 2013 | 245 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 344 | 0.090 |
Why?
|
| Kidney | 1 | 2014 | 289 | 0.090 |
Why?
|
| Disease Progression | 4 | 2015 | 479 | 0.090 |
Why?
|
| AC133 Antigen | 1 | 2011 | 7 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 87 | 0.090 |
Why?
|
| Antigens, CD | 1 | 2011 | 140 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2011 | 124 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 88 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 154 | 0.080 |
Why?
|
| ErbB Receptors | 3 | 2018 | 100 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 4 | 2017 | 1661 | 0.080 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 285 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 275 | 0.070 |
Why?
|
| Fruit | 1 | 2021 | 40 | 0.040 |
Why?
|
| Triglycerides | 1 | 2022 | 123 | 0.040 |
Why?
|
| Plant Extracts | 1 | 2021 | 62 | 0.040 |
Why?
|
| Dinoprostone | 1 | 2021 | 42 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 29 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2021 | 105 | 0.040 |
Why?
|
| Fatty Acid Synthases | 1 | 2020 | 7 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2020 | 13 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2021 | 135 | 0.040 |
Why?
|
| Alleles | 1 | 2021 | 357 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2022 | 152 | 0.040 |
Why?
|
| Proteomics | 1 | 2022 | 197 | 0.040 |
Why?
|
| Quinoxalines | 1 | 2019 | 17 | 0.040 |
Why?
|
| Benzodiazepinones | 1 | 2019 | 13 | 0.040 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 17 | 0.040 |
Why?
|
| Prognosis | 1 | 2022 | 812 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2019 | 153 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2019 | 73 | 0.040 |
Why?
|
| Celecoxib | 1 | 2018 | 10 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 123 | 0.040 |
Why?
|
| Hemostasis | 1 | 2018 | 48 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 74 | 0.030 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2018 | 4 | 0.030 |
Why?
|
| Food, Formulated | 1 | 2017 | 11 | 0.030 |
Why?
|
| Emulsifying Agents | 1 | 2017 | 7 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 77 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 164 | 0.030 |
Why?
|
| Catechin | 1 | 2016 | 13 | 0.030 |
Why?
|
| Lignans | 1 | 2016 | 10 | 0.030 |
Why?
|
| Isothiocyanates | 1 | 2016 | 11 | 0.030 |
Why?
|
| Glutamine | 1 | 2016 | 32 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2016 | 24 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2016 | 33 | 0.030 |
Why?
|
| Polyphenols | 1 | 2016 | 18 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2016 | 55 | 0.030 |
Why?
|
| Arachidonate 5-Lipoxygenase | 1 | 2015 | 12 | 0.030 |
Why?
|
| Arginine | 1 | 2016 | 42 | 0.030 |
Why?
|
| Nitrosamines | 1 | 2015 | 5 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2015 | 5 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2015 | 19 | 0.030 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2016 | 68 | 0.030 |
Why?
|
| Ceruletide | 1 | 2015 | 7 | 0.030 |
Why?
|
| bcl-X Protein | 1 | 2015 | 35 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2015 | 19 | 0.030 |
Why?
|
| Micronutrients | 1 | 2016 | 49 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 236 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 288 | 0.030 |
Why?
|
| Stilbenes | 1 | 2016 | 91 | 0.030 |
Why?
|
| Transfection | 1 | 2016 | 319 | 0.030 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 1 | 2014 | 2 | 0.030 |
Why?
|
| Nicotine | 1 | 2015 | 86 | 0.030 |
Why?
|
| Radioisotopes | 1 | 2014 | 11 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2014 | 22 | 0.030 |
Why?
|
| Alanine | 1 | 2014 | 40 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 433 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 413 | 0.030 |
Why?
|
| Diet | 1 | 2016 | 241 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 314 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2014 | 332 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 461 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 876 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2015 | 303 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 114 | 0.020 |
Why?
|